The firm has partnered with the University of Surrey to validate and potentially commercialize a test that detects mRNA biomarkers from patient urine samples.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology.
Among its business highlights for the quarter, the firm established coverage for the Afirma genomic sequencing classifier by all major insurance plans.
The assay is based on real-time reverse transcriptase PCR that will identify Zika in human serum or urine.